Antibodies News and Research

RSS

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly using a new laboratory technique developed by an international research team collaborating with the National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2004

Anal cancer is on the rise in both sexes

Anal cancer is on the rise in both sexes, particularly among American men, and changing trends in sexual behavior — combined with current tobacco use and infection by a specific strain of the human papillomavirus — may help explain the increase.

9 Jul 2004

A new protocol for bone marrow transplants

A new protocol for bone marrow transplants, which does not require the destruction of the recipient’s immune system before transfer of the new bone marrow, is described by a group of Oxford scientists

5 Jul 2004

Rabies infections in organ donor and transplant recipients

On June 30, 2004, CDC confirmed diagnoses of rabies in three recipients of transplanted organs and in their common donor, who was found subsequently to have serologic evidence of rabies infection.

2 Jul 2004

Findings into the source of the recent SARS outbreak in Beijing and Anhui Province

It has been more than two months since the Ministry of Health of China notified WHO and the world about an outbreak of SARS in Beijing and Anhui Province.

2 Jul 2004

Oxford Therapeutic Antibody Centre receives Manufacturer’s Authorisation

Oxford University's Therapeutic Antibody Centre (TAC) has received a Manufacturer's Authorisation (Investigational Medicinal Products) from the Medicines and Healthcare Products Regulatory Agency (MHRA).

29 Jun 2004

12 sites testing a new vaccine to prevent anthrax

The phase II trial will evaluate the safety and immunogenic response of a new recombinant anthrax vaccine, known as rPA102. The vaccine candidate consists of recombinant Protective Antigen (rPA), a synthetic protein that induces antibodies designed to prevent illness by neutralizing anthrax toxins, and aluminum hydroxide to enhance the immune response.

29 Jun 2004

Launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies

Mattel Children's Hospital at UCLA announced the launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies at UCLA June 28.

29 Jun 2004

Naturally occurring genetic change in humans that dramatically increases muscle size and strength

A research team funded by MDA has discovered a naturally occurring genetic change (mutation) in humans that dramatically increases muscle size and strength.

28 Jun 2004

HHS has extended the availability of a recently approved rapid oral HIV test

"These actions will expand even further the availability of a simple, rapid HIV test to communities where people are at high risk of HIV," Secretary Thompson said. "HIV testing has never been easier or more accessible than it is today.

26 Jun 2004

A single dose of a test vaccine sprayed into the nose protects monkeys against the SARS virus

The study, published in the June 26 issue of the British journal The Lancet, is the third recently issued by NIAID that describes a promising candidate vaccine against SARS.

25 Jun 2004

Animal vaccine shows potential for the development of human SARS immunisation

The current issue of the LANCET provides evidence for the effectiveness of experimental SARS immunisation in animal studies. The preliminary results show the potential for the development of human SARS immunisation.

24 Jun 2004

Treating cocaine addiction with a virus

Scientists at The Scripps Research Institute have designed a potentially valuable tool for treating cocaine addiction by creating a modified "phage" virus that soaks up the drug inside the brain.

24 Jun 2004

New patent for screening technology

MorphoSys AG announced today that the U.S. Patent & Trademark Office has granted a new patent on its proprietary CysDisplay™ screening technology.

24 Jun 2004

European marketing approval for new influenza vaccine

Solvay Pharmaceuticals announced today that it has obtained European marketing approval for its new virosomal influenza vaccine: INVIVAC®.

23 Jun 2004

Harmless virus known as GBV-C slows the progression of HIV

Iowa City Veterans Affairs (VA) Medical Center and University of Iowa (UI) researchers have unlocked part of the mystery of how a harmless virus known as GBV-C slows the progression of HIV and prolongs survival for many patients.

17 Jun 2004

Ultrasound technology to treat cancer

Ultrasound scans might be most familiar for getting a peek at a developing fetus, but the technology could also be used to treat cancer. A partnership between UC Davis, Siemens Medical Systems and ImaRx Inc., funded by a National Cancer Institute grant, will study ways to deliver drugs to tumors using focused ultrasound.

17 Jun 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

Findings could explain why island populations worldwide are particularly susceptible to disease

Researchers have shown that Darwin's finches on smaller islands in the Galapagos archipelago have weaker immune responses to disease and foreign pathogens---findings that could help explain why island populations worldwide are particularly susceptible to disease.

15 Jun 2004